Coleman D L, Barry M
Am J Trop Med Hyg. 1982 Jan;31(1):71-4. doi: 10.4269/ajtmh.1982.31.71.
Clinical trials of bithionol in treating Paragonimus westermani lung infection have been conducted in areas of endemic infection. Bithionol has been reported to cure over 90% of infected patients. We report a case of a 32-year-old Laotian man residing in Connecticut who relapsed with P. westermani pneumonitis 4 months after apparent eradication of infection with bithionol (40 mg/kg by mouth every other day for 10 doses). He was successfully treated with a second course of bithionol (40 mg/kg by mouth every other day for 15 doses). The mechanism of relapse of P. westermani infection following bithionol therapy should be evaluated.
在肺吸虫感染流行地区开展了硫双二氯酚治疗卫氏并殖吸虫肺部感染的临床试验。据报道，硫双二氯酚可治愈90%以上的感染患者。我们报告了一例32岁居住在康涅狄格州的老挝男子，在用硫双二氯酚（40mg/kg口服，隔日一次，共10剂）明显根除感染4个月后，卫氏并殖吸虫肺炎复发。他接受了第二个疗程的硫双二氯酚治疗（40mg/kg口服，隔日一次，共15剂）并获成功。应评估硫双二氯酚治疗后卫氏并殖吸虫感染复发的机制。
